```html

Hepatocellular Carcinoma (HCC) – Comprehensive Medical Guide

Overview

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, arising from the hepatocytes (the main cells of the liver). It accounts for roughly 75–85 % of all liver cancers worldwide.<sup>1</sup> HCC typically develops in a liver that is already diseased—most often cirrhosis caused by chronic hepatitis B (HBV) or hepatitis C (HCV) infection, alcohol‑related liver disease, or non‑alcoholic steatohepatitis (NASH).

While HCC can occur at any age, the median age at diagnosis is between 60 and 70 years. Male sex is a major risk factor; men are about 2–4 times more likely to develop HCC than women.<sup>2</sup> Globally, an estimated 905,000 new cases and 830,000 deaths occur each year, making liver cancer the fourth leading cause of cancer mortality.<sup>3</sup>

Symptoms

Early HCC often produces no symptoms, which is why regular surveillance in high‑risk individuals is crucial. When symptoms appear, they may be vague or overlap with other liver conditions.

• Abdominal pain or discomfort – usually dull pain in the right upper quadrant.
• Unexplained weight loss – loss of appetite and a feeling of early satiety.
• Fatigue – persistent tiredness that is not relieved by rest.
• Jaundice – yellowing of the skin and eyes caused by elevated bilirubin.
• Hepatomegaly – an enlarged liver that may be felt on physical exam.
• Ascites – accumulation of fluid in the abdomen, leading to swelling and discomfort.
• Upper gastrointestinal bleeding – vomiting blood (hematemesis) or black, tarry stool (melena) from variceal hemorrhage.
• Fever – low‑grade fever without an obvious source.
• Pruritus (itching) – due to cholestasis.
• Muscle wasting (cachexia) – advanced disease may cause severe loss of muscle mass.

Causes and Risk Factors

Primary Causes

1. Chronic hepatitis B infection – HBV DNA integrates into the host genome, driving oncogenesis. In endemic areas (sub‑Saharan Africa, East Asia) HBV alone can cause HCC without cirrhosis.
2. Chronic hepatitis C infection – HCV induces chronic inflammation and fibrosis, leading to cirrhosis and HCC.
3. Alcoholic liver disease – heavy, long‑term alcohol use (≥60 g/day for men, ≥40 g/day for women) accelerates cirrhoscotic changes.
4. Non‑alcoholic fatty liver disease (NAFLD) / NASH – growing cause in Western countries; obesity, type 2 diabetes, and metabolic syndrome are central contributors.
5. Aflatoxin exposure – toxin produced by Aspergillus species contaminating stored grains and nuts, especially in warm, humid climates.

Additional Risk Factors

• Male gender
• Age > 50 years (risk rises sharply after 60)
• Family history of HCC or chronic viral hepatitis
• Genetic disorders: hereditary hemochromatosis, α‑1 antitrypsin deficiency, Wilson disease.
• Diabetes mellitus – increases risk independent of NAFLD.
• Cigarette smoking – contributes to liver inflammation and fibrosis.
• Obesity (BMI ≥ 30 kg/m²) – linked to NASH‑related HCC.
• Exposure to certain chemicals (e.g., vinyl chloride, thorium dioxide).

Diagnosis

Diagnosing HCC requires a combination of imaging, laboratory tests, and sometimes tissue sampling. The approach is guided by the American Association for the Study of Liver Diseases (AASLD) algorithm.

1. Laboratory Evaluation

• Alpha‑fetoprotein (AFP) – elevated in ~60 % of HCC patients; a level > 400 ng/mL is highly suggestive, though normal AFP does not exclude HCC.
• Complete blood count, liver function panel (ALT, AST, bilirubin, albumin, INR), and viral hepatitis serologies.
• Serum des‑γ‑carboxyprothrombin (DCP) – used in some Asian guidelines as an adjunct marker.

2. Imaging Studies

1. Multiphasic contrast‑enhanced CT or MRI – the cornerstone. Typical HCC shows arterial phase hyperenhancement followed by “wash‑out” in the portal venous or delayed phases.
2. Contrast‑enhanced ultrasound (CEUS) – useful when CT/MRI are contraindicated; assesses vascular pattern in real time.
3. Gadolinium‑enhanced MRI with hepatocyte‑specific agents (e.g., gadoxetate disodium) – improves detection of small lesions (< 2 cm).

3. Biopsy

Historically required, but modern imaging criteria often allow a non‑invasive diagnosis. Biopsy is reserved for:

• Lesions that do not meet radiologic criteria.
• Cases where the diagnosis will alter management (e.g., distinguishing HCC from cholangiocarcinoma).

4. Staging

Staging determines prognosis and guides therapy. The most widely used system is BCLC (Barcelona Clinic Liver Cancer), which incorporates tumor burden, liver function (Child‑Pugh), performance status, and cancer‑related symptoms. Other staging tools include AJCC/TNM and the CLIP score.

Treatment Options

Treatment is individualized based on tumor stage, liver reserve, and patient comorbidities. Options fall into curative, locoregional, systemic, and supportive categories.

Curative‑Intent Therapies

• Surgical resection – preferred for solitary tumors with well‑preserved liver function (Child‑Pugh A/B). 5‑year survival ranges 50–70 %.
• Liver transplantation – offers the best long‑term outcomes for patients meeting Milan criteria (≤ 3 lesions ≤ 3 cm each, or a single lesion ≤ 5 cm) and acceptable portal hypertension. Post‑transplant 5‑year survival exceeds 70 %.
• Ablative therapies – radiofrequency ablation (RFA) or microwave ablation for tumors ≤ 3 cm, especially when surgery is contraindicated.

Locoregional (Non‑Curative) Therapies

• Transarterial chemoembolization (TACE) – delivers chemotherapy directly to the tumor while occluding its arterial supply; standard for intermediate‑stage disease.
• Transarterial radioembolization (TARE) – Yttrium‑90 microspheres provide internal radiation; useful for portal vein thrombosis.
• Selective internal radiation therapy (SIRT) – similar to TARE, often combined with systemic agents.

Systemic Therapies

First‑line systemic options for advanced HCC (BCLC stage C) include:

• Atezolizumab + bevacizumab – immune checkpoint inhibitor plus anti‑VEGF; superior overall survival vs. sorafenib in the IMbrave150 trial.<sup>4</sup>
• Sorafenib – multikinase inhibitor; long‑standing standard.
• Lenvatinib – non‑inferior to sorafenib with a distinct side‑effect profile.
• Second‑line agents: regorafenib, cabozantinib, ramucirumab (for AFP ≥ 400 ng/mL), and immunotherapies (nivolumab, pembrolizumab) for patients progressing after first‑line.

Supportive & Lifestyle Measures

• Management of underlying liver disease (antiviral therapy for HBV/HCV, abstinence from alcohol, weight loss for NAFLD/NASH).
• Vaccination against hepatitis A and B if not immune.
• Nutrition counseling – high‑protein, low‑sodium diet to mitigate ascites and preserve muscle mass.
• Regular exercise within tolerance – improves fatigue and sarcopenia.
• Pain control and psychosocial support.

Living with Hepatocellular Carcinoma

1. Follow‑up Schedule

After curative treatment, most guidelines recommend imaging (contrast CT or MRI) and AFP measurement every 3–6 months for the first 2 years, then every 6–12 months thereafter.

2. Managing Side Effects

• Fatigue – schedule rest periods, prioritize sleep hygiene, and engage in light activity.
• Ascites – limit sodium (< 2 g/day), use diuretics (spironolactone + furosemide), and monitor weight daily.
• Upper GI bleeding – propranolol or carvedilol for portal hypertension; endoscopic band ligation if varices are present.
• Medication toxicities – report hand‑foot skin reaction, hypertension, or severe diarrhea promptly; dose adjustments may be needed.

3. Emotional & Practical Support

• Join liver‑cancer support groups (online or in‑person).
• Consider counseling or psychiatric evaluation for anxiety/depression.
• Plan advance directives and discuss goals of care with your care team early.
• Engage a multidisciplinary team: hepatologist, oncologist, surgeon, dietitian, social worker, and palliative‑care specialist.

Prevention

Because most HCC arises in a diseased liver, preventing the underlying liver injury is the most effective strategy.

• Vaccinate against hepatitis B – universal newborn vaccination has reduced HBV‑related HCC dramatically in endemic regions.
• Screen and treat chronic hepatitis C – direct‑acting antivirals achieve > 95 % cure rates, dramatically lowering HCC risk.
• Limit alcohol intake – guidelines advise ≤ 14 g/day for women and ≤ 28 g/day for men.
• Maintain a healthy weight – aim for BMI 18.5–24.9 kg/m²; weight loss of 5–10 % improves NASH histology.
• Avoid aflatoxin exposure – store grains in dry conditions, discard moldy food.
• Regular surveillance – high‑risk patients (cirrhosis, chronic HBV with high viral load) should undergo ultrasound ± AFP every 6 months per AASLD recommendations.<sup>5</sup>

Complications if Untreated

• Liver failure – progressive loss of hepatic synthetic function (coagulopathy, encephalopathy).
• Portal hypertension – variceal bleeding, refractory ascites, splenomegaly.
• Metastasis – spread to lungs, bones, lymph nodes, and adrenal glands.
• Cachexia – severe weight loss and muscle wasting, leading to functional decline.
• Spontaneous tumor rupture – intraperitoneal hemorrhage, a life‑threatening emergency.

When to Seek Emergency Care

---

Sources:

1. CDC – Liver Cancer Basics
2. Mayo Clinic – Liver Cancer
3. IARC – Global Cancer Statistics 2020
4. NEJM – Atezolizumab plus Bevacizumab in Unresectable HCC
5. CDC – Hepatocellular Carcinoma Surveillance

```